Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17

This article was originally published in The Pink Sheet Daily

Executive Summary

ZymoGenetics and commercialization partner Bayer will use the three-month extension to hone plans for “aggressively converting the market,” firm tells “The Pink Sheet” DAILY.

You may also be interested in...



ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks

Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.

ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks

Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.

Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel

Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel